<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01224353</url>
  </required_header>
  <id_info>
    <org_study_id>NM2010001</org_study_id>
    <nct_id>NCT01224353</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Thioctacid Oral Tablets 600mg to Treat Chinese Diabetic Patients With Distal Symmetric Polyneuropathy</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Thioctacid Oral Tablet 600mg Once Daily in Chinese Diabetic Patients With Distal Symmetric Polyneuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovaMed Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovaMed Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy on overall neuropathic sensory symptom
      improvement of Thioctacid tablet 600mg once daily vs. placebo in 6-weeks' treatment in
      Chinese diabetic patients with distal symmetric polyneuropathy (DSP).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">July 2011</completion_date>
  <primary_completion_date type="Anticipated">May 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy on overall neuropathic sensory symptom improvement of Thioctacid tablet 600mg once daily vs. placebo in 6-weeks' treatment in Chinese diabetic patients with distal symmetric polyneuropathy (DSP)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Changes from baseline in Total Symptom Score (TSS) from week 1 to week 6 will be computed and summarized in an Area Under the Curve (AUC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate each sensory symptom improvement of Thioctacid tablet 600mg once daily vs. placebo in 6-weeks' treatment in Chinese diabetic patients with DSP</measure>
    <time_frame>6 weeks</time_frame>
    <description>Changes in the individual symptom scores of the TSS (Stabbing pain, burning, paraesthesia, numbness)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate onset time of Thioctacid tablet 600mg once daily vs. placebo in 6-weeks' treatment in Chinese diabetic patients with DSP</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate response rate of Thioctacid tablet 600mg once daily vs. placebo in 6-weeks' treatment in Chinese diabetic patients with DSP</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the tolerability and safety of Thioctacid tablet 600mg once daily vs. placebo in 6-weeks' treatment in Chinese diabetic patients with DSP</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of adverse events and standard laboratory tests will be the Measures of Safety and Tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Diabetics</condition>
  <arm_group>
    <arm_group_label>Thioctacid Oral Placebo Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Thioctacid Oral Tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lipoic acid</intervention_name>
    <description>Tablet, 600mg, for oral use, 30 min before breakfast, once daily for 6 weeks</description>
    <arm_group_label>Thioctacid Oral Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, placebo, 1-week single-blind placebo treatment then, 30 min before breakfast, once daily for 6 weeks</description>
    <arm_group_label>Thioctacid Oral Placebo Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must fulfil all of the following criteria to be appropriate to enter into
             Registry (Visit 2)

               1. Provision of informed consent

               2. Females and males aged from 18 to 75 (inclusive), who were definitely diagnosed
                  with diabetes

               3. HbA1C&lt; 10％

               4. Moderate neuropathy according to Neuropathy Disability Score (NDS) &gt;= 4 points.
                  Difference in score between left and right foot is not to be higher than 2 points

               5. Total Symptom Score (TSS) &gt; 6.5 points

               6. At least one of the four symptoms of the TSS has occurred continuously over the
                  last 3 months before screening

               7. Other concomitant treatments (the drugs and their dosage) have been stable over 1
                  month before screening Subjects must fulfil all of the following criteria before
                  randomization：

               8. TSS &gt; 5 points

               9. TSS range (maximum TSS - minimum TSS during Run-in Period) &lt; 3 points during the
                  Run-in Period

              10. Compliance in Run-in Period &gt; 85%

        Exclusion Criteria:

          1. Neurologic disease other than diabetic neuropathy that may produce weakness, sensory
             loss, or autonomic symptoms or test abnormality

          2. Peripheral vascular disease severe enough to cause intermittent claudication or
             ischemic ulcers

          3. Patients who have been hospitalized due to glucopenia or ketoacidosis in the last 3
             month

          4. Present ulcers on lower limbs of any cause

          5. Antioxidant therapy within the last 1 month before screening (Vitamin E&gt; 400IU,
             Vitamin C&gt; 200mg once daily for continuous 2 weeks)

          6. Any ALA therapy within the last1 month before screening

          7. Opioid analgesic therapy within the last 1 month before screening

          8. History of mental, psychological or behavioral conditions rendering the patient unable
             to follow the protocol

          9. History of malignant tumors in the past 5 years except for basal cell carcinoma

         10. Any severe systematic diseases, at the investigator's discretion, which will make it
             undesirable for the patient to participate in the trial or which could jeopardize
             compliance with the trial protocol,

         11. ALT or AST &gt; 2.5 ´ upper limit of reference range

         12. Cr &gt; 1.8mg/dL ( &gt; 159µmol/L) for males or &gt; 1.6mg/dL ( &gt; 141µmol/L) for females

         13. History of hypersensitive to the active ingredients or excipients of ALA

         14. Participation in a clinical study or treatment with a non-approved experimental
             medication in the last 1 month

         15. Pregnant or breast-feeding women, or women of childbearing age without appropriate
             contraception measures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qi Wan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Provincial People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jiangsu Provincial People's Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qi Wan</last_name>
      <phone>86 13770316989</phone>
      <email>qi_wan@126.com</email>
    </contact>
    <investigator>
      <last_name>Jie Gong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qi Wan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ping Gu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Nantong University</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <zip>226001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kaifu Ke</last_name>
      <phone>0513-85052569</phone>
      <email>kekaifu_nt@126.com</email>
    </contact>
    <investigator>
      <last_name>Maohong Cao</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kaifu Ke</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aihong Li</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heqing Zhao</last_name>
      <phone>86 13004571960</phone>
      <email>zhao_heqing@163.com</email>
    </contact>
    <investigator>
      <last_name>Heqing Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xia Zhang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weidong Hu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wanli Dong</last_name>
      <phone>86 512 65223637</phone>
      <phone_ext>8317</phone_ext>
      <email>dwlsz@163.com</email>
    </contact>
    <investigator>
      <last_name>Wanli Dong</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shouru Xue</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaowei Hu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hongxia Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuxi No.2 People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuenan Kong</last_name>
      <phone>86 051267727501</phone>
      <phone_ext>3503</phone_ext>
      <email>kkyynn2008@yahoo.cn</email>
    </contact>
    <investigator>
      <last_name>Yuenan Kong</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wenzhuo Dai</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tao Ma</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2010</study_first_submitted>
  <study_first_submitted_qc>October 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2010</study_first_posted>
  <last_update_submitted>October 19, 2010</last_update_submitted>
  <last_update_submitted_qc>October 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Wan Qi/Director</name_title>
    <organization>Neuropathic Department, Jiangsu Provincial People's Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

